Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6115631 | Diagnostic Microbiology and Infectious Disease | 2016 | 17 Pages |
Abstract
Among 302 first candidemia episodes, 210 (69.6%) were initially treated with an echinocandin or polyene (E/P) antifungal drug. In 137 (72.5%) patients with fluconazole-susceptible isolates, treatment was changed to fluconazole based on disk diffusion susceptibility testing. Clinical outcomes were not compromised in patients receiving E/P who were de-escalated to fluconazole for treatment of candidemia based on disk diffusion results.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
David W. Kubiak, Dimitrios Farmakiotis, Viktoria Arons, Randy M. Hollins, Sara E. Rostas, Linda M. Weiser, Lindsey R. Baden, Francisco M. Marty, Sophia Koo,